influenza vaccine (Assistance publique - Hôpitaux de Paris)

The influenza vaccine (Assistance Publique - Hôpitaux de Paris) refers to the seasonal influenza vaccines, specifically Mutagrip and Vaxigrip, evaluated in clinical trials sponsored by the Assistance Publique - Hôpitaux de Paris (AP-HP), such as the MICIVAX study. These vaccines are inactivated, split-virion preparations containing hemagglutinin antigens from three or four influenza virus strains (typically two Influenza A subtypes, H1N1 and H3N2, and one or two Influenza B lineages) as recommended by the World Health Organization for the Northern Hemisphere. The vaccine is administered via intramuscular injection to stimulate the production of neutralizing antibodies against the viral hemagglutinin, thereby preventing infection and reducing the severity of influenza. In the context of AP-HP research, these vaccines have been studied for their safety and immunogenicity in specific populations, including patients with inflammatory bowel disease (IBD) who may be receiving immunosuppressive therapy.

Brand names

MutagripVaxigripPanenza

Other names

MICIVAX vaccineinfluenza vaccine (Assistance Publique - Hôpitaux de Paris)